BMRA
Biomerica, Inc.
BMRA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BMRA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BMRA's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BMRA PE Valuation
BMRA has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BMRA's losses to grow, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.67 | -$0.15 |
| Q2 2026 | -$1.30 | +$0.86 |
| Q1 2026 | -$1.45 | +$0.87 |
| Q4 2025 | -$1.49 | +$1.23 |
| Q3 2025 | -$1.52 | +$1.44 |
| Q2 2025 | -$2.16 | +$0.72 |
| Q1 2025 | -$2.32 | +$0.64 |
| Q4 2024 | -$2.72 | +$0.32 |
BMRA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BMRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3M | -8.3% |
| Q2 2026 | $875K | +17% |
| Q1 2026 | $987K | -12% |
| Q4 2025 | $1.2M | -26% |
| Q3 2025 | $1.4M | -24% |
| Q2 2025 | $749K | -33% |
| Q1 2025 | $1.1M | +10% |
| Q4 2024 | $1.6M | +4.4% |
BMRA's revenue has slid since its 2022 peak: $1M last quarter, down 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -97% | -16 points |
| Q2 2026 | -175% | +34 points |
| Q1 2026 | -132% | -23 points |
| Q4 2025 | -113% | -53 points |
| Q3 2025 | -81% | -5.3 points |
| Q2 2025 | -209% | -72 points |
| Q1 2025 | -108% | +89 points |
| Q4 2024 | -61% | +42 points |
BMRA's operating margin was −97% last quarter, down 16 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BMRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BMRA on profitability, with a higher operating margin.
BMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$802K | -$534K |
| Q2 2026 | -$912K | -$251K |
| Q2 2025 | -$661K | +$407K |
| Q2 2024 | -$1.1M | -$105.2K |
| Q1 2024 | -$1.8M | -$70.4K |
| Q4 2023 | -$848K | +$389.7K |
| Q3 2023 | -$1.7M | -$88.1K |
| Q2 2023 | -$962.8K | +$3.3M |
BMRA has burned cash in almost every quarter: −$4M over the past year, against −$4M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BMRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +286K shares |
| 1 year | +43% | +999K shares |
| 3 years | +86% | +1.5M shares |
| 5 years | +121% | +1.8M shares |
| Available history | +169% | +2.1M shares |
BMRA has 3M diluted shares, up 43% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BMRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BMRA Net Leverage
BMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.9 | Oversold |
BMRA's weekly RSI is 34 (neutral) and its Stochastic is 11 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BMRA PE vs Healthcare Sector
BMRA has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 28% below |
| 20 week MA | $1.83 | 29% below |
| 50 week MA | $2.08 | 38% below |
| 100 week MA | $2.83 | 54% below |
| 200 week MA | $5.62 | 77% below |
BMRA is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $39.8 | +84% |
| 2021 | $39.8 | $33.6 | -15% |
| 2022 | $33.6 | $29.7 | -12% |
| 2023 | $29.7 | $10.0 | -66% |
| 2024 | $10.0 | $2.52 | -75% |
| 2025 | $2.52 | $2.70 | +7.1% |
| 2026 YTD | $2.70 | $1.30 | -52% |
BMRA has finished lower in four of the last six years. It's down 52% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BMRA on returns for 2026, with the stronger performance.